Three main strategies exist for hypoxia-targeted tumour treatments: (1) combination therapy to increase oxygen concentrations in tumours; (2) pre-bioreduction drugs conversion into active metabolites via an enzymatic reduction in hypoxia tumour environments; (3) small molecule inhibitors that modulate molecular targets involved in tumour cell survival in hypoxic tissue, such as hypoxia-inducible factor-1α (HIF-1α) [96,97]. This evidence concerns the gene HIF1A and neoplasm.